Literature DB >> 23709357

Optimizing outcomes in major depressive disorder via augmentation therapy--focus on the role of atypical antipsychotics. Foreword.

J Craig Nelson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23709357     DOI: 10.1007/s40263-012-0027-9

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  3 in total

1.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

2.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

3.  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.

Authors:  J Craig Nelson; George I Papakostas
Journal:  Am J Psychiatry       Date:  2009-08-17       Impact factor: 18.112

  3 in total
  1 in total

1.  Factors associated with antipsychotic use in non-psychotic depressed patients: results from a clinical multicenter survey.

Authors:  Jingjing Zhou; Tong Zhu; Xuequan Zhu; Britta Galling; Le Xiao
Journal:  BMC Psychiatry       Date:  2022-02-03       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.